A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Early Breast Cancer
Interventions: DRUG: Pertuzumab IV|DRUG: Trastuzumab IV|DRUG: Pertuzumab and Trastuzumab FDC SC|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Docetaxel|PROCEDURE: Surgery|RADIATION: Post-Operative Radiotherapy|DRUG: Hormone Therapy
Sponsor: Hoffmann-La Roche